Clinical Trial Update: Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of RAD001 in mantle cell lymphoma patients refractory or intolerant to Velcade therapy has completed with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• RAD001 (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphoma, Mantle- Cell | Phase 2 | Status: COMPLETED | Results posted: 2021-05-25